The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Triplet therapy with BRAF inhibitor, anti-EGFR agent, and MEK inhibitor in V600E BRAF–mutant colorectal cancer: A meta-analysis.
 
Michela Guardascione
Travel, Accommodations, Expenses - MSD (Inst)
 
Fabiola Giudici
No Relationships to Disclose
 
Paola Di Nardo
Travel, Accommodations, Expenses - Astrazeneca (Inst); Lilly Medical (Inst); Roche Italy (Inst)
 
Simone Rota
No Relationships to Disclose
 
Riccardo Vida
No Relationships to Disclose
 
Elena Ongaro
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; MSD; SERVIER
 
Arianna Fumagalli
Travel, Accommodations, Expenses - Novartis (Inst); PharmaMar (Inst)
 
Marco de Scordilli
Expert Testimony - AstraZeneca (Inst)
 
Luisa Foltran
Travel, Accommodations, Expenses - AstraZeneca (Inst)
 
Fabio Puglisi
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo Europe GmbH; Eisai; Gilead Sciences; Italfarmaco; Lilly; Menarini; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Viatris
Research Funding - AstraZeneca; Eisai; Roche
Travel, Accommodations, Expenses - Amgen; Astrazeneca; Celgene; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Pfizer; Roche